Glaxosmithkline Share Price | |
---|---|
Price | 1,649.50 |
Bid | 1,649.50 |
Ask | 1,650.00 |
Change | 13.50 (0.83%) |
Volume | 1,676,189 |
Open | 1,642.00 |
High | 1,656.00 |
Low | 1,635.00 |
Prev. Close | 1,636.00 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.09b |
Market Capitalisation | £67.40b |
Market Size | 1,500 |
52 Week High | 1,719.80 |
52 Week High Date | 07-Mar-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 4,174 |
---|---|
Vol. Sold | 703,066 |
Sold Value | £11.58m |
Vol. Bought | 721,556 |
Bought Value | £11.89m |
PE Ratio | 13.56497 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.365% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
25-Apr-24 | 12:39:59 | 1,648.50 | 175 | Sell* | 1,649.50 | 1,650.00 | 2,885 | O Ordinary |
25-Apr-24 | 12:40:01 | 1,649.50 | 276 | Buy* | 1,649.00 | 1,650.00 | 4,553 | A Automatic Execution |
25-Apr-24 | 12:40:01 | 1,649.50 | 265 | Buy* | 1,649.00 | 1,649.50 | 4,371 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 48 | Buy* | 1,648.50 | 1,649.50 | 791.76 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 480 | Buy* | 1,648.50 | 1,649.50 | 7,918 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 385 | Buy* | 1,648.50 | 1,649.50 | 6,351 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 49 | Buy* | 1,648.50 | 1,649.50 | 808.26 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 49 | Buy* | 1,648.50 | 1,649.50 | 808.26 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 49 | Buy* | 1,648.50 | 1,649.50 | 808.26 | A Automatic Execution |
25-Apr-24 | 12:40:00 | 1,649.50 | 49 | Buy* | 1,648.50 | 1,649.50 | 808.26 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
19-Apr-24 | 16-Apr-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 39.79 | USD | 2,906,213 | 3,370,704 |
19-Apr-24 | 16-Apr-24 | Buy Dividends | Emma Walmsley held the position of CEO at the time of this trade.Emma Walmsley | 1,611.28 | GBX | 1,840,922 | 2,190,842 |
15-Apr-24 | 12-Apr-24 | Buy Dividends | Anne Beal held the position of Independent Non-Executive Director at the time of this trade.Anne Beal | 40.96 | USD | 9 | 3,375 |
15-Apr-24 | 12-Apr-24 | Buy Dividends | Harry (Hal) C. Dietz held the position of Independent Non-Executive Director at the time of this trade.Harry (Hal) C. Dietz | 40.96 | USD | 9 | 3,118 |
15-Apr-24 | 12-Apr-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 40.96 | USD | 13 | 464,491 |
At GSK, we unite science, technology and talent to get ahead of disease together